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Abstract
CgPdr1p is a Candida glabrata Zn(2)-Cys(6) transcription factor involved in the regulation of the ABC-transporter genes
CgCDR1, CgCDR2, and CgSNQ2, which are mediators of azole resistance. Single-point mutations in CgPDR1 are known to
increase the expression of at least CgCDR1 and CgCDR2 and thus to contribute to azole resistance of clinical isolates. In this
study, we investigated the incidence of CgPDR1 mutations in a large collection of clinical isolates and tested their relevance,
not only to azole resistance in vitro and in vivo, but also to virulence. The comparison of CgPDR1 alleles from azole-
susceptible and azole-resistant matched isolates enabled the identification of 57 amino acid substitutions, each positioned
in distinct CgPDR1 alleles. These substitutions, which could be grouped into three different ‘‘hot spots,’’ were gain of
function (GOF) mutations since they conferred hyperactivity to CgPdr1p revealed by constitutive high expression of ABC-
transporter genes. Interestingly, the major transporters involved in azole resistance (CgCDR1, CgCDR2, and CgSNQ2) were
not always coordinately expressed in presence of specific CgPDR1 GOF mutations, thus suggesting that these are rather
trans-acting elements (GOF in CgPDR1) than cis-acting elements (promoters) that lead to azole resistance by upregulating
specific combinations of ABC-transporter genes. Moreover, C. glabrata isolates complemented with CgPDR1 hyperactive
alleles were not only more virulent in mice than those with wild type alleles, but they also gained fitness in the same animal
model. The presence of CgPDR1 hyperactive alleles also contributed to fluconazole treatment failure in the mouse model. In
conclusion, this study shows for the first time that CgPDR1 mutations are not only responsible for in vitro/in vivo azole
resistance but that they can also confer a selective advantage under host conditions.
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Introduction
Candida glabrata has recently emerged as the second most
common cause of invasive candidiasis, and there are increasing
numbers of reports showing its important role in mucosal or
bloodstream infections [1,2]. Systemic infections due to C. glabrata
are characterized by a high mortality rate, and they are difficult to
treat due to the intrinsically low susceptibility of this species to
azole drugs, especially to fluconazole [3]. In addition, C. glabrata
easily develops fluconazole resistance in response to drug exposure
during patient treatment [4–6].
Azole antifungals target the cytochrome P-450 lanosterol 14-a
demethylase, encoded by ERG11. Resistance of yeast clinical
isolates to azole antifungal agents can result from either
overexpression or mutations in ERG11. Alternatively, the cells
can fail to accumulate azole antifungal agents due to enhanced
drug efflux, a consequence of transcriptional activation of drug
efflux pumps (for review, see [7]). At least two families of multidrug
transporters, the ABC (ATP-binding cassette) transporter family
and the major facilitator superfamily (MFS), are involved in azole
resistance. In C. glabrata, the constitutive upregulated expression of
ABC-transporter genes CgCDR1 and, to a lesser extent, CgCDR2
(also known as PDH1) plays a dominant role in azole resistance
[4,8–11]. Each of these genes can be upregulated in C. glabrata
clinical isolates and disruption of CgCDR1 or CgCDR1/CgCDR2
leads to hypersusceptibility to fluconazole, cycloheximide, and
chloramphenicol [4,9,10,12,13].
The expression of CgCDR genes is regulated by a single Zn(2)-
Cys(6) transcription factor, CgPdr1p, an homologue of S. cerevisiae
Pdr1p/Pdr3p [11]. CgPDR1 deletion leads to a loss of CgCDR1 and
CgCDR2 regulation and to a sharp increase in azole susceptibility
[14]. Due to the presence of PDRE (pleiotropic drug response
element) sequences in the CgCDR1 and CgCDR2 promoters,
CgPdr1p acts probably by binding to these regulatory elements as
Pdr1p and Pdr3p in S. cerevisiae. CgPDR1 contains a PDRE in its
promoter suggesting an auto-regulation of its transcription.
Consistent with this observation, upregulation of CgCDR1 and
CgCDR2 in azole-resistant strains is correlated with an increase of
PLoS Pathogens | www.plospathogens.org 1 January 2009 | Volume 5 | Issue 1 | e1000268CgPDR1 expression [14,15]. CgPDR1 is also essential in azole
resistance caused by mitochondrial dysfunction in C. glabrata petite
mutants. Since enhanced CgPDR1 expression is observed in some
petite mutants, it has been proposed that CgPDR1 regulates its own
expression in response to mitochondrial dysfunction [15].
CgPdr1p acts as nuclear receptor by directly binding to diverse
drugs and xenobiotics, such as azoles, to activate expression of
efflux pumps genes resulting in multidrug resistance [16]. The
activation domain of CgPdr1p binds directly to the Mediator co-
activator subunit CgGal11p in a xenobiotic-dependent manner in
order to activate transcription of target genes [16].
Two studies have identified three separate amino acid
substitutions (W297S, F575L, P927L) in CgPdr1p of azole-
resistant strains that are responsible for constitutive high
expression of CgCDR1, CgCDR2 and CgPDR1 itself [14,15].
Recently, another Pdr1p-regulated ABC-transporter gene,
CgSNQ2, was shown to participate to azole resistance of C. glabrata
clinical isolates [17]. In this study, a fourth CgPdr1p amino
substitution, P822L, was identified. Interestingly, the P822L
substitution is responsible for the constitutive overexpression of
CgSNQ2, but has no effect on the expression of CgCDR1 and
CgCDR2 [17].
In the present study, we investigated the incidence of CgPDR1
mutations in a large collection of clinical isolates. Because no study
has yet addressed whether the presence of CgPDR1 mutations is
correlated with fitness costs in C. glabrata, we engineered isogenic
strains with individual CgPDR1 mutations and tested their
virulence in two different animal models. The strains that acquired
in vitro azole resistance were used to test the in vivo response to
fluconazole. We observed a high diversity among CgPDR1 alleles
and identified 57 distinct single amino acid substitutions, which
may confer hyperactivity to CgPdr1p in order to mediate high
expression of ABC transporter genes. Although CgCDR1, CgCDR2
and CgSNQ2 are all regulated by CgPdr1p, they are not always
coordinately expressed in azole-resistant isolates indicating that
ABC transporter genes were differentially regulated depending on
the mutation present on the CgPDR1 allele. Finally, the identified
amino acid substitutions in CgPdr1p enhanced virulence and led
to fluconazole treatment failure in mouse models. Taken together
our data demonstrate a high variability in CgPDR1 mutations,
which themselves have differentiated effects on target genes
including ABC-transporters and probably on yet unidentified
virulence factors.
Results
Isolation and Characterization of CgPDR1 Alleles from C.
glabrata Clinical Isolates
The incidence of CgPDR1 mutations was investigated in a
collection of C. glabrata clinical isolates (n=122) consisting of 30
groups of sequential isolates (n=66). Each group contained at least
one azole-susceptible (MIC fluconazole#16 mg/ml) and one
azole-resistant (MIC fluconazole$32 mg/ml) isolates, which were
shown to be highly related by genotyping methods (Cg6 and Cg12
repetition probes or MLST) (data not shown). There were 36
azole-resistant isolates among the groups of related isolates. The
56 remaining isolates were unrelated (41 azole-resistant and 15
azole-susceptible, Table S1). In this collection, azole-resistant
isolates upregulated at least one of the ABC-transporter genes
including CgCDR1, CgCDR2 or CgSNQ2 (see Figure 1 for ABC-
transporter genes expression levels measured by real-time RT-
PCR in groups of isolates and Figure S1 for CgCdr1p and
CgCdr2p levels determined by western blot). CgPDR1 from each
isolate was cloned and sequenced. To determine nucleotide
polymorphisms, the 122 sequences were aligned and showed 66
non-synonymous nucleotide substitutions among a total of 70
distinct CgPDR1 alleles. By comparison of CgPDR1 alleles from
azole-susceptible and azole-resistant isolates, we identified 12
different alleles recovered only from azole-susceptible isolates
containing combinations of eight different mutations and 58
different alleles specific for azole-resistant isolates with 58 distinct
mutations. These mutations yielded 57 single amino acid
substitutions (Table S2) located at 50 locations along the protein
and encompassing three distinct protein domains: i) the region
similar to the transcriptional inhibitory domain of Pdr1p from S.
cerevisiae, ii) the middle homology region (MHR) and iii) a putative
transcriptional activation domain (Figure 2). Eleven distinct amino
acids substitutions were found repeatedly in azole-resistant
resistant isolates (six found twice and five found three times) and
several substitutions occurred at the same position in six different
cases (Table S2). Overall, CgPdr1p unique substitutions were
found in 46 distinct azole-resistant isolates. This suggests that
saturation of CgPDR1 mutations in azole-resistant isolates may be
still not reached. Indeed, a parallel and independent CgPDR1
sequence analysis of ten azole-resistant C. glabrata isolates still
revealed one unknown mutation and two additional distinct
mutations on one of the 51 nucleotide positions identified in this
study (O. Bader, unpublished). We hypothesized that CgPDR1
mutations may confer enhanced activity (or hyperactivity) to
CgPdr1p leading to increased expression of the CgCDR and/or
CgSNQ2 genes.
Azole resistance was generally correlated with the occurrence of
mutations in CgPDR1, except in four azole-resistant isolates
(DSY717, DSY2282, DSY2325 and BPY41). Mitochondrial
dysfunction is one of the possible mechanism by which azole
resistance can occur during azole treatment of patients [18].
Indeed, three isolates (DSY2282, DSY2325 and BPY41) displayed
altered mitochondrial respiratory capacity as deduced from their
inability to grow on medium containing glycerol as sole carbon
source and from their defects in mitochondrial DNA (Figure S2).
Although CgCDR1 was upregulated in the remaining isolate
Author Summary
Candida glabrata is a yeast causing several diseases in
humans and especially in immuno-compromised people.
C. glabrata infections are treated with antifungal agents,
however the use of some agents, for example azoles, is
associated with the development of resistance. In this
yeast species, azole resistance is mediated almost exclu-
sively by ATP Binding Cassette (ABC) multidrug transport-
ers. Their overexpression results in enhanced efflux of
azoles and thus generates resistance. Regulation of ABC
transporters is therefore of pivotal importance to under-
standing azole resistance. In C. glabrata, the expression of
ABC transporters is mediated by a zinc finger transcription
factor called CgPDR1. Gain of function (GOF) mutations in
CgPDR1 result in high ABC transporter expression. In this
study, we investigated the occurrence of GOF mutations in
a large collection of azole-resistant isolates and found a
high variety of mutations localized in three distinct
domains of CgPDR1. We found that these mutations are
not only associated with resistance but also enhanced
virulence and fitness of C. glabrata in animal models. Our
study provides for the first time evidence that mutations
causing antifungal resistance can also provide a selective
advantage under host conditions and thus highlights the
need of carefully monitoring resistance in this pathogen.
Azole Resistance and Impact on Virulence
PLoS Pathogens | www.plospathogens.org 2 January 2009 | Volume 5 | Issue 1 | e1000268Figure 1. Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata azole-resistant isolates from groups of sequential clinical
isolates. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in
gene expression relative to the azole-susceptible parental strains (set at 1.00). Error bars show standard deviations.
doi:10.1371/journal.ppat.1000268.g001
Figure 2. Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both
azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for
CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region)
were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with
Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.
doi:10.1371/journal.ppat.1000268.g002
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currently investigating azole resistance in this isolate and these
data will be reported elsewhere.
CgPDR1 Expression Levels Have a Moderate Effect on
Azole Resistance
Single point mutations in CgPDR1 have been shown to increase
the expression of both CgCDR genes and CgPDR1, thus
contributing to azole resistance of clinical isolates [14,15]. To
evaluate whether the expression level of CgPDR1 is important for
the upregulation of CgCDR genes in our isolates, the CgPDR1
mRNA levels of 21 matched pairs of azole-susceptible and azole-
resistant isolates (listed in Table 1) were quantified by slot blot
analysis and real-time RT-PCR (Figure 3). The comparison
between CgPDR1 expression levels from azole-susceptible and
azole-resistant matched isolates yielded comparable results as
judged by similar relative increase of CgPDR1 expression obtained
with the two methods (Figure 3). We concluded from these results
that CgPDR1 upregulation was not correlating with azole
resistance since CgPDR1 was overexpressed up to two-fold in
some resistant isolates (DSY2268, DSY565, DSY756) as compared
to their matched azole-susceptible isolate, whereas it was similarly
expressed in others (DSY2257, DSY2277, DSY2271) (Figure 3).
To determine whether the two-fold increase in CgPDR1
expression observed in some isolates was sufficient to induce high
levels of CgCdr1p and CgCdr2p and thus azole resistance,
CgPDR1 alleles from an azole-susceptible and an azole-resistant
matched isolate (DSY2235 and DSY2234, respectively) were
cloned into the CEN-ARS plasmid pCgACU-5 [19] and expressed
in a strain lacking CgPDR1. The CgPDR1 alleles from DSY2235
and DSY2234 only differ by the amino acid substitution T588A.
Expression of CgPDR1 alleles from the episomal plasmid resulted
in a three- to four-fold increase of CgPDR1 mRNA in the revertant
strains as compared to the clinical isolates (Figure 4A), but no
significant change was observed in CgCdr1p and CgCdr2p levels
and in azole susceptibility (Figure 4B and 4C). Similar results were
obtained by overexpressing other mutated CgPDR1 alleles (data
not shown), indicating that the slight increase in CgPDR1
expression observed in some resistant isolates could not account
for azole resistance.
CgPDR1 Mutations Induce Azole Resistance
The identified CgPDR1 mutations were next investigated for
their ability to confer hyperactivity to CgPdr1p by mediating high
expression of ABC-transporter genes resulting in azole resistance.
For this purpose, CgPDR1 was first inactivated in a pair of azole-
susceptible and azole-resistant isolates (DSY562 and DSY565,
respectively) and reintroduced at the CgPDR1 genomic locus by
homologous recombination in the obtained pdr1D strains. CgPDR1
alleles from these two isolates only differ by the amino acid
substitution L280F in the putative inhibitory domain of CgPdr1p.
Disruption of CgPDR1 in both azole-susceptible and azole-resistant
isolates led to a drastic increase of azole susceptibility and to the
complete downregulation of both CgCDR genes (Figure 5A and
5B), thus confirming the involvement of CgPdr1p in azole
resistance. Each DSY562 and DSY565 pdr1D mutant received
the CgPDR1 wild type or mutated alleles. Expression of CgCDR1,
CgCDR2 and CgSNQ2 in reconstituted strains was restored to
similar levels than those of the original clinical isolates (Figure 5B).
Expression of the CgPDR1 allele containing the L280F substitution
was sufficient to confer CgCdr1p and CgCdr2p constitutive high
expression and thus azole resistance in C. glabrata independently on
the strain genetic background (Figure 5C).
Table 1. Azole susceptibilities and CgPDR1 mutations from C.
glabrata clinical isolates.
Strain Site of isolation CgPDR1 mutation
b MIC (mgm l
21)
a
FLC
c ITC
c KTC
c
DSY486 Oropharynx - 16 1 1
DSY489 Oropharynx L328F (G984T) 128 2 2
DSY738 Oropharynx - 8 0.5 1
DSY739 Oropharynx R376W (C1126T) 64 2 2
DSY2253 Oropharynx - 16 1 1
DSY2254 Oropharynx D1082G (A3245G) 128 2 2
DSY2235 Oropharynx - 4 0.125 0.125
DSY2234 Oropharynx T588A (A1762G) 32 1 1
DSY701 Oropharynx 4 0.25 0.25
DSY704 Oropharynx T607S (C1820G) 32 1 1
DSY529 Oropharynx - 4 0.5 0.5
DSY530 Oropharynx E1083Q (G3247C) 64 2 2
DSY753 Oropharynx - 4 0.125 0.125
DSY754 Oropharynx Y584C (A1751G) 32 1 1
DSY726 Oropharynx - 8 0.25 0.25
DSY727 Oropharynx D876Y (G2626T) 64 2 2
DSY562 Oropharynx - 8 0.125 0.125
DSY565 Oropharynx I280F (G840C) 128 2 2
DSY2256 Oropharynx - 4 2 1
DSY2257 Oropharynx N691D (A2071G) 32 1 1
DSY759 Oropharynx - 4 0.5 0.125
DSY2268 Oropharynx S316I (G947T) 32 1 1
DSY2270 Oropharynx - 8 1 1
DSY2271 Oropharynx D261G (A782G) 128 2 2
DSY2272 Oropharynx - 4 0.5 0.5
DSY2273 Oropharynx R293I (G878T) 32 2 1
DSY2276 Oropharynx - 8 0.5 0.5
DSY2277 Oropharynx R592S (G1776C) 32 2 1
DSY2278 Oropharynx - 4 0.5 0.5
DSY2279 Oropharynx G583S (G1747A) 32 0.5 0.5
DSY2281 Oropharynx - 8 0.25 0.25
DSY2282 Oropharynx - 64 2 1
DSY755 Oropharynx - 4 0.25 0.125
DSY756 Oropharynx S343F (C1028T) 128 2 2
DSY2316 Oropharynx - 8 1 1
DSY2315 Oropharynx R376G (C1126G) 32 1 1
DSY773 Oropharynx - 16 0.5 1
DSY774 Oropharynx R376G (C1126G) 32 1 1
DSY2317 Oropharynx - 4 0.25 0.5
DSY717 Oropharynx - 64 2 2
DSY2324 Oropharynx - 4 0.25 0.125
DSY2325 Oropharynx - 128 2 2
aMICs to these antifungal agents were determined by broth microdilution
method in accordance with the CLSI M27-A2 document (National Committee
for Clinical Laboratory Standards, 2002).
bNumbers correspond to the positions of amino acid changes while numbers in
parentheses correspond to the position of changed nucleotides changed in
CgPDR1 relative to the ATG start codon.
cFLC: Fluconazole; ITC: itraconazole; KTC: ketoconazole.
doi:10.1371/journal.ppat.1000268.t001
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(Table 1) were reintroduced at the CgPDR1 genomic locus in an
azole-susceptible background lacking CgPDR1. CgPDR1 alleles
from each pair of isolates only differ by a point mutation leading to
a single amino acid substitution in either the inhibitory domain,
the MHR or the activation domain of CgPdr1p. These mutations,
which were specific for azole-resistant isolates, restored azole
resistance in a pdr1D mutant (fluconazole MICs from 64–128 mg/
ml, Figure 6A). Since only alleles containing these mutations
conferred CgCDR1 constitutive high expression (from 4- to 150-
fold expression increase, Figure 6B), these mutations could be
assigned as GOF mutations. Moreover, single amino acid
substitutions in either the inhibitory domain, the MHR or the
activation domain could confer drug resistance. Once again,
altered CgPDR1 expression could not account for azole resistance,
since the CgPDR1 mRNA levels were similar between the clinical
strains and the revertant strains expressing their corresponding
CgPDR1 alleles (Figure S3).
Distinct CgPDR1 GOF Mutations Have Differentiated
Effects on ABC-Transporter Genes Expression
To determine the effect of distinct mutated CgPDR1 alleles on
ABC-transporter genes expression, mRNA levels of CgCDR1,
CgCDR2 and CgSNQ2 were determined by real-time RT-PCR in
21 matched pairs of azole-susceptible and azole-resistant isolates
clinical isolates listed in Table 1 (Figure 1). As previously observed
by Torelli et al. [17], CgCDR1, CgCDR2 and CgSNQ2 were not
always coordinately expressed in azole-resistant isolates. Among
them, CgSNQ2 showed in general the lowest expression variations.
Taking a significant upregulation between two isolates as a
threshold of two-fold expression difference, only nine isolates were
above this value. CgSNQ2 was more upregulated (8.5-fold) than the
other ABC transporters only in DSY2277 (Figure 1). Upregulation
of CgCDR1 and CgCDR2 in azole-resistant isolates followed similar
patterns but without reaching statistical significance (data not
shown). In some cases, significant upregulation (from 13- to 170-
fold) of only CgCDR1 was measured (DSY2268, DSY2273,
Figure 3. Expression of CgPDR1 in matched pairs of azole-susceptible (S) and azole-resistant (R) isolates. RNA was isolated from log
phase cultures, slot-blotted to membranes and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in
blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1.
Expression values represent the increase of CgPDR1 expression in azole-resistant isolates relative to their azole-susceptible parental strains. RNA was
also used for real-time quantitative RT-PCR as described in Material and Methods. Values given on the right diagram are means (6SEM) of three
separate experiments and express CgPDR1 relative expression in resistant isolates as compared to their matched susceptible parents.
doi:10.1371/journal.ppat.1000268.g003
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(DSY2254 and DSY2234), CgCDR2 upregulation outreached that
of CgCDR1 (Figure 1). Since the three ABC-transporter genes are
regulated by CgPDR1, their uncoordinated expression might be
explained by either differences in their promoter sequences or by
differences in the transcriptional capacity of CgPdr1p. To avoid
differences due to strain genetic backgrounds, pairs of CgPDR1
alleles were reintroduced in the same background (DSY562
pdr1D). mRNA levels of CgCDR1, CgCDR2 and CgSNQ2 were
measured by real-time RT-PCR in the revertant strains (Figure 6B)
and compared with those obtained in the clinical isolates (Figure 1).
For example, the presence of the Y584C substitution (from
CgPDR1 of DSY754) led to CgCDR1 upregulation only (17- and
12-fold expression increase, Figure 1 and Figure 6B), whereas the
presence of the T588A substitution (from CgPDR1 of DSY2234)
resulted in high mRNA levels of both CgCDR genes (4- and 8-fold
expression increase for CgCDR1, 23- and 30-fold increase for
CgCDR2, Figure 1 and Figure 6B). Finally the presence of the
P822L substitution (from CgPDR1 of BPY55) in a pdr1D mutant
resulted in the upregulation of CgSNQ2 only (15-fold, Figure 6B),
which is consistent with previous observation made in this clinical
isolate [17]. These results as well as those obtained with other
engineered isolates were overall consistent with expression profiles
from clinical isolates containing the same CgPDR1 alleles (Figure 1)
and thus indicate that ABC-transporter genes might be differen-
tially regulated depending on the CgPDR1 GOF mutation and
independently on the strain background.
CgPDR1 GOF Mutations Are Responsible for Increased
Virulence of C. glabrata
The C. glabrata isolates analysed in this study are of clinical
origin. These isolates may have adapted to the host conditions in
order to cause disease. Moreover, azole therapy in these patients
selected for azole-resistant isolates and ultimately led to treatment
failure. One interesting and unresolved question is whether
CgPDR1 mutations responsible for high transporter expression
have an impact on virulence and fitness of C. glabrata under host
conditions. We therefore first measured tissue fungal burdens in
animal models using tail-vein injections in groups of immuno-
competent and immuno-suppressed mice according to previously
established protocols [20–22]. Fungal loads in kidneys, spleen and
liver of all mice were measured seven days after infection. We next
performed virulence assays by measuring mice survival after
infection with several C. glabrata isolates to challenge correlations
between virulence and possible differences in tissue fungal loads.
Using first DSY562 and DSY565 in immuno-competent or
immuno-suppressed mice (Figure 7A and 7B), our results showed
that fungal loads in kidneys were significantly increased in both
mouse models infected with DSY565 as compared to DSY562
(P,0.0001 and P=0.0007, respectively; see details in Table S3).
The same trend was observed in fungal loads of spleen and liver
(Figure S4). Higher fungal loads in tissues of mice infected with the
azole-resistant isolate DSY565 correlated with a significant
increased virulence as compared to DSY562 (Figure 8A). Taken
together, these results demonstrate that the azole-resistant isolate
(DSY565) was more virulent than its azole-susceptible parent,
DSY562. Since DSY562 and DSY565 differ at least by the
presence of the L280F substitution in CgPDR1, it was tempting to
test whether this substitution was responsible for this behavior. We
therefore replaced the mutated allele with the CgPDR1 wild type
allele in DSY565 (named as DSY565 pdr1D-PDR1; SFY118) and
also replaced the CgPDR1 wild type allele with the mutated allele
in DSY562 (named as DSY562 pdr1D-L280F; SFY115). CgPDR1
alleles were also reconstituted in their original backgrounds
(DSY562 pdr1D-PDR1; SFY114 and DSY565 pdr1D-L280F;
SFY119). Mice infected with DSY562 pdr1D-L280F or DSY565
pdr1D-L280F had significant higher fungal loads in their kidneys
as compared to DSY565 pdr1D-PDR1 or DSY562 pdr1D-PDR1
(Figure 7A, P,0.0001). The same was observed in immuno-
suppressed mice (Figure 7B, P,0.0001). No significant changes in
kidneys fungal loads occurred between immuno-competent mice
Figure 4. Effect of CgPDR1 expression on azole resistance. (A)
Expression of CgPDR1 in a matched pair of azole-susceptible and azole-
resistant isolates (DSY2235 and DSY2234), in revertant strains (‘‘rev’’)
overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1D
mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each
strain (‘‘DSY’’ for clinical strains and ‘‘rev’’ for revertant strains) were
named according to their strain number origin. RNA was isolated from
log phase cultures, slot-blotted to membranes, and hybridized with the
indicated gene probes. CgACT1 served as internal control. Signals
obtained in blotted membranes were quantified by counting radioac-
tivity by phosphor imaging. Signals obtained for CgPDR1 were
normalized with CgACT1 and substracted from background. Expression
values represent the increase of CgPDR1 expression in revertant strains
relative to the clinical isolates expressing the same CgPDR1 allele. (B)
Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235
and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and
of a pdr1D mutant (SFY53). Isolates were grown on YPD medium
containing the drug at the indicated concentration at 30uC for two
days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata
clinical isolates DSY2235 and DSY2234, in revertant strains (rev)
overexpressing CgPDR1 alleles in a pdr1D mutant (SFY53). Proteins
extract were separated by SDS-10% PAGE and immunoblotted with
rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as
described previously [9]. MICs to fluconazole were determined by
broth microdilution method in accordance with the CLSI M27-A2
document (National Committee for Clinical Laboratory Standards, 2002).
doi:10.1371/journal.ppat.1000268.g004
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with DSY562 pdr1D-PDR1 and DSY565 pdr1D-PDR1 (P=0.62).
Virulence assays with the same strains confirmed the association of
increased virulence with increased fungal loads of infected tissues
(Figure 8A). Thus, increased virulence was associated with the
presence of a GOF mutation in CgPDR1 independently on the
strain background. Introducing other mutations in the background
of DSY562 mimicked results of fungal tissue burdens and of
virulence assays obtained with the first tested CgPDR1 mutant
allele (see results obtained with DSY562 pdr1D-T588A, -Q1083Q,
-P822L and DSY562 pdr1D-P822L, Figure 7 and Figure 8B) and
thus one can predict that increased virulence may be caused by
any of the GOF mutations so far identified in CgPDR1.
Interestingly, the absence of CgPDR1 in DSY562 (DSY562 pdr1D;
SFY92) did not significantly alter fungal tissue burdens and
virulence in animal models (Figure 7 and Figure 8A). This strongly
Figure 5. Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical
isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at
30uC for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1D: SFY92; DSY565 pdr1D: SFY94; DSY562 pdr1D+562
(standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1D+565
L280F (standing for re-introduction of CgPDR1 from DSY565 with
L280F substitution): SFY115; DSY565pdr1D+562: SFY118; DSY565 pdr1D+565
L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C.
glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are
averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard
deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins
extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described
previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.
doi:10.1371/journal.ppat.1000268.g005
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presence of CgPDR1 that directly affects virulence.
This assumption is also based on fitness tests performed in vitro
and in vivo with two selected isolates, each containing a wild type
(DSY562 pdr1D-PDR1; SFY114) or a mutated CgPDR1 allele
(DSY562 pdr1D-L280F; SFY115). We observed that a GOF
mutation had no selective advantage in vitro for C. glabrata over a
susceptible parent isolate since both strains cultivated over 24 h at
a 1:1 population ratio remained in equivalent population
proportions (Figure 9A). It is only in vivo that the azole-resistant
population displayed a selective advantage over susceptible
isolates. After inoculating mice with a 1:1 population ratio, a
progressive disappearance of the susceptible population was visible
over the time lapse of the animal experiment (Figure 9B). These
results demonstrate that a GOF in CgPDR1 is associated with a
gain in fitness in vivo even in the absence of drug selection.
Figure 6. Reconstitution of CgPDR1 GOF alleles in C. glabrata. (A) Fluconazole susceptibility testing of DSY562 pdr1D mutant strain (SFY93)
expressing different CgPDR1 alleles, which were named according to their strain number origin and by indicating the amino acid substitution (in
superscript) associated with a specific strain number. The following strains correspond to the indicated genotypes: DSY562 pdr1D+486:SFY98;
489
L328F: SFY99; 738: SFY100; 739
R376W: SFY101; 2253: SFY102; 2254
D1082G:SFY103; 2235: SFY104; 2234
T588A: SFY105; 701: SFY106; 704
T607S: SFY107;
529:SFY108; 530
E1083Q: SFY109; 753: SFY110; 754
Y584C: SFY111; 726: SFY112; 727
D876Y: SFY113; BPY55
P882L: SFY116. (B) Expression of CgCDR1, CgCDR2,
and CgSNQ2 in the DSY562 pdr1D mutant strain (SFY93) expressing different CgPDR1 alleles, named according to their strain number origin.
Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene
expression relative to DSY562 (set at 1.00). Error bars show standard deviations.
doi:10.1371/journal.ppat.1000268.g006
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infected intravenously with 4610
7 viable cells of C. glabrata strains. Mice were sacrificed at day 7 post-infection; and results, which are expressed as
CFUs per gram of tissue, represent values recorded separately for each of the ten mice. Geometric means are indicated by horizontal bars and
asterisks indicate statistically significant differences (*: P,0.05; **: P,0.01; ***: P,0.001). NS indicates no significance (P.0.05). The origin of each
strain is indicated. Strain background (DSY562 or DSY565) is indicated by filled or empty symbols, respectively. The pdr1D mutants from strains
DSY562 and DSY565 correspond to SFY92 and SFY94, respectively. Revertants constructed from pdr1D mutants are indicated by the re-introduced
GOF mutation or by the re-introduced wild type CgPDR1 allele from DSY562. Prism 5.0 was used for statistical analysis and data were processed with
non-parametric Wilocoxon Rank sum tests. Comparisons are indicated in the Figure (see Table S3 for details) and associate selected data points. (B)
Fungal tissue burdens in kidneys from immuno-suppressed mice infected intravenously with 4610
7 viable cells of C. glabrata strains. BALB/c mice
were rendered neutropenic by intraperitoneal administration of cyclophosphamide (200 mg kg
21 of body weight per day) three days before
challenge and on the day of infection. Mice were sacrificed at day 7 post-infection.
doi:10.1371/journal.ppat.1000268.g007
Azole Resistance and Impact on Virulence
PLoS Pathogens | www.plospathogens.org 9 January 2009 | Volume 5 | Issue 1 | e1000268CgPDR1 GOF Mutations Affect the In Vivo Response to
Fluconazole
Since DSY565 is resistant to azoles in vitro, we expected little
changes between tissue burden of mice infected with this clinical
isolate in fluconazole-treated or -untreated conditions. The data
obtained after measurement of colony forming units (CFU) from
tissues of treated versus untreated animals infected with this strain
confirmed this hypothesis only in spleen and liver (Figure S5,
P=0.39 and 0.82), while partially in kidneys (Figure 10, P=0.04).
These results contrasted with those obtained with the azole-
susceptible isolate DSY562: a sharp and significant decrease of
fungal load was observed in all organs when comparing treated
versus untreated animals (P,0.0001–0.03). The absence of
CgPDR1 in both DSY562 and DSY565 backgrounds resulted in
this experimental setting in a three-log decrease of fungal loads
when animal were treated with fluconazole. This result could be
expected from in vitro susceptibility data that yielded for these
mutants the lowest fluconazole MIC values (Figure 5C). This
suggests that CgPDR1 is essential for the response of C. glabrata to
fluconazole challenge in vivo. Reconstituting wild type isolates from
DSY562 and DSY565 backgrounds with a CgPDR1 wild type
allele (DSY562 pdr1D-PDR1: SFY114; DSY565 pdr1D-PDR1:
SFY118) gave in terms of fluconazole efficacy similar results to
those obtained with the starting clinical isolate DSY562 (Figure 10).
With the exception of DSY562 pdr1D-T588A (P=0.02), the
reconstitution of GOF mutations in CgPDR1 in both DSY562
(DSY562 pdr1D–Q1083Q, -P822L) and DSY565 (DSY565
pdr1D-L280F, -P822L) gave by CFU counts in kidneys no
significant differences between fluconazole-treated and untreated
animals. However, CFU counts of spleen and liver of animals
infected with DSY562 pdr1D-T588A were not significantly
different from untreated animals upon fluconazole treatment
(P=0.28 and 0.16), thus suggesting that this GOF was still
responsible for treatment failure. Taken together, our results are in
agreement with the idea that high fluconazole MIC values are
mirrored by treatment failure in this animal model. Moreover, our
results demonstrate the critical role of CgPDR1 for the adequate
response of C. glabrata to fluconazole challenge. On the other hand,
our results also highlight that CgPDR1 GOF mutations alone are
responsible for fluconazole treatment failure in the experimental
model tested here.
Discussion
CgPdr1p is a Zn(2)-Cys(6) transcription factor involved in the
regulation of the ABC-transporter genes CgCDR1, CgCDR2 and
CgSNQ2, which are responsible for azole resistance in C. glabrata.
Figure 8. Virulence of C. glabrata is dependent on CgPDR1 GOF mutations. (A) Survival curves of mice infected with DSY562 and DSY565 and
derived mutants and revertants. Statistical differences were performed using the Log-rank Mantel-Cox test (Prism 5.0) by comparing survival curveso f
mice infected by DSY562 and by other strains as indicated. The range of significant P values obtained is indicated for DSY565 and strains containing
the CgPDR1 allele with a L280F substitution. (B) Survival curves of mice infected with DSY562 and DSY565 and strains reconstituted with different
CgPDR1 alleles. The range of significant P values obtained is indicated for DSY565 and strains containing GOF mutations.
doi:10.1371/journal.ppat.1000268.g008
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P822L and P927L) have been reported to increase the expression
of at least CgCDR1, CgCDR2 and CgSNQ2 and thus to contribute to
azole resistance of clinical isolates [14,15]. This work allowed the
identification of 57 additional substitutions in CgPdr1p localized in
three main ‘‘hot spots’’ near the so-called inhibitory domain, the
MHR and the transcriptional activation domain.
CgPDR1: The Expected and the Non-Expected
Nine distinct mutations in CgPDR1 alleles, three in each of the
‘‘hot spots’’ domains, conferred constitutive upregulation of ABC-
transporter genes when expressed in an azole-susceptible back-
ground and thus can be considered as true GOF mutations
responsible for azole resistance in C. glabrata. The 48 other
mutations are also likely GOF mutations since they are present
only in alleles isolated from azole-resistant strains upregulating
ABC-transporter genes and the localization of these mutations
along the protein is similar to GOF mutations described in the S.
cerevisiae homologs Pdr1p/Pdr3p. Most GOF mutations in PDR3
map to the first two motifs of the inhibitory domain and to the
transcriptional activation domain [23]. In contrast, PDR1
mutations are scattered throughout the entire protein with some
‘‘hot spots’’ at the C-terminus [24]. Given the high diversity of
GOF mutations found in CgPDR1, it is unlikely that all mutations
affect similarly the transcriptional activity of CgPdr1p that is
responsible for ABC-transporter genes overexpression. Hence,
GOF mutations in the inhibitory domain might impair transcrip-
tional inhibition and those in the transcriptional activation might
induce hyperactivation as proposed for PDR3 mutations in S.
cerevisiae.
The effect of some of the identified GOF mutations might be
enlightened by the recent finding that CgPdr1p acts as nuclear
receptor by directly binding to azoles in order to activate
expression of efflux pumps genes [16]. For instance, the xenobiotic
binding domain of S. cerevisiae Pdr1p has been mapped between
amino acids 352 and 543, and this domain corresponds by
sequence alignment to the MHR region of CgPdr1p. GOF
mutations in the MHR might bypass the requirement of
xenobiotic binding that is otherwise necessary to activate the
transcription of efflux pumps genes. Determining whether CgPDR1
alleles containing mutations in the MHR domain could still be
induced by azoles may verify this hypothesis. Once bound to
azoles, CgPdr1p forms a complex with the Mediator co-activator
subunit CgGal11p though the KIX motif to activate transcription
of target genes. The CgPdr1p KIX-binding domain has been
mapped between amino acids 1074 to 1104 [16]. Interestingly, we
Figure 9. Fitness assays between azole-resistant and azole-susceptible isolates. (A) In vitro fitness assays. Strains SFY114 (DSY562 pdr1D-
PDR1) and SFY115 (DSY562 pdr1D-L280F) were inoculated in YEPD in single or mixed (1:1) cultures. Aliquots were taken from each culture in triplicate
and population ratios were calculated from the proportion of azole-susceptible and azole-resistant colonies plated onto YEPD agar as described in
Material and Methods. (B) In vivo fitness assays. SFY114 (DSY562 pdr1D-PDR1) and SFY115 (DSY562 pdr1D-L280F) were inoculated intravenously as
single or mixed (1:1) cultures to three groups of mice as described in Material and Methods. Kidneys were taken at given time points from sacrificed
mice and population ratios were measured as described above.
doi:10.1371/journal.ppat.1000268.g009
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suggesting that GOF mutations might modify CgGal11p recruit-
ment in absence of drug binding.
It is now well established that S. cerevisiae Pdr1p and Pdr3p act
through cis acting sites present in the promoters of target genes.
The consensus motif is named PDRE (for pleiotropic drug
resistance element) and is present in several ABC-transporter
gene promoters such as PDR5, SNQ2 and YOR1 [25]. In C. glabrata,
a genome-wide study identified genes upregulated by a CgPDR1
GOF mutant and, by analysis of the promoters, the sequence 59-
TCC(GA)(CT)GAA-39 was identified as a strong candidate for C.
glabrata PDRE. This sequence is found in the promoters of
CgCDR1, CgCDR2 and CgSNQ2, suggesting that CgPdr1p binds
directly to PDRE sequences to regulate transcription of target
genes [14,15,17]. Surprisingly, our results show that CgCDR1,
CgCDR2 and CgSNQ2 are not coordinately expressed in azole-
resistant isolates. Moreover, the selective upregulation of efflux
pump genes is dependent on the CgPDR1 GOF alleles, since
expression of distinct mutated alleles in the same genetic
background restored the ABC-transporter gene expression of the
parental clinical strains from which the alleles were isolated. This
observation highlights still underscored and novel functions of
CgPDR1 on the regulation of target genes. One possible
explanation for these differentiated effects could be the localization
of the mutations that may alter the transcriptional activity of
CgPdr1p. However, data presented here indicate that mutations
within the same domain do not yield similar ABC-transporter
expression patterns. For example, two distinct mutations in the
KIX domain, E1083Q (in DSY530) and D1082G (in DSY2254),
gave selective upregulation of CgCDR1 alone or both CgCDR1 and
CgCDR2, respectively. On the other hand, differences in the
number and/or sequence of the PDRE present in the efflux pump
promoters could influence CgPdr1p regulatory activity. Alterna-
tively, the function of CgPdr1p might be subjected to regulation by
other transcription factors. Irrespective of the precise molecular
mechanism involved, our results strongly suggest that CgPDR1
GOF mutations have differentiated effects on target genes
including the major ABC-transporters involved in azole resistance.
Microarray experiments performed with individual CgPDR1
mutations would help determining whether other target genes
are differentially expressed and promoter analysis may provide
clues to uncover this mechanism.
The presence of a PDRE sequence in the promoter of CgPDR1
as well as the constitutive high expression of CgPDR1 in some
azole-resistant isolates suggested an auto-regulation similarly to
PDR3 [14,15,26]. Moreover, enhanced CgPDR1 expression was
also observed in some petite mutants [15]. It has thus been
proposed that CgPDR1 may regulate its own expression leading to
azole resistance. However, results presented here suggest that
CgPDR1 upregulation is restricted to a limited number of azole-
resistant isolates and does not correlate with the presence of GOF
mutations. The increase in CgPDR1 expression observed in our
strains is not sufficient per se to induce azole resistance. This
observation is consistent with a recent study demonstrating that
CgPDR1 expression is poorly correlated with azole resistance in C.
glabrata [27]. Even though our experimental approaches were
different from published studies, especially with respect to the
engineering of mutant and revertant strains, the regulation of
CgPDR1 needs to be further investigated.
CgPDR1 and Effects on C. glabrata-Host Interactions
During the last decades, there has been a significant increase in
the appearance of resistance in C. glabrata as a result of an
increased use of azoles combined with the exceptional ability of
this yeast species to develop resistance. In bacteria, antimicrobial
resistance is often associated with fitness costs and thus results in a
competitive disadvantage against otherwise drug-susceptible
bacteria within the host [28]. Restoration of fitness in drug-
resistant bacteria is often associated with the emergence of
compensatory mutations [29]. A few examples illustrate that
Figure 10. Efficacy of azole treatment in C. glabrata assessed by fungal tissue burden in kidneys. Fluconazole (100 mg/Kg/day) was
administered by intraperitoneal injection in immuno-suppressed mice as described in Material and Methods. Treatment was initiated 24 h after
inoculation (day 1 post-infection) and continued until day 7 post-infection. Mice were injected with 4610
7 CFU of each investigated strain and organ
homogenates were obtained from ten mice per group that were sacrificed and necropsied on day 8 post-infection. Results, which are expressed as
CFUs per gram of tissue, represent means of values recorded separately for each of the mice. Geometric means are indicated by horizontal bars and
asterisks indicate statistically significant differences between two conditions (see legend of Figure 7 and Table S3 for details). Closed and empty
circles indicate CFU from untreated and fluconazole-treated animals infected with a DSY562 background, respectively. Closed and empty diamonds
indicate CFU from untreated and fluconazole-treated isolates with a DSY565 background, respectively.
doi:10.1371/journal.ppat.1000268.g010
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beneficial in the fitness of pathogenic bacteria [30,31]. Implicit
in this reasoning is that antifungal resistance may have fitness costs
in fungi and thus may result in a counter-selection against resistant
strains without drug pressure. Whether resistance similarly exerts a
relevant fitness cost that is associated with diminished virulence in
fungi is still debated [28]. One study has addressed this question in
C. albicans by testing the virulence of azole-resistant isolates
compared to their azole-susceptible parental isolate [32]. The
authors concluded that no direct relationship exists between the
development of azole resistance and virulence. In vitro studies
showed that individual C. albicans colonies subcultured in
fluconazole-containing medium can follow individual emergence
of azole resistance mechanisms. Some of these trajectories can be
associated with an immediate decrease in fitness (measured by
reduced growth rate). However fitness is restored by further
cultivation by still unknown compensatory mechanisms [33].
Other studies suggest that once the selective pressure eases, the
fungal-resistant strains will disappear [34–36].
Testing the interplay between C. glabrata and the host requires a
validated animal model. Existing studies have mostly used
intravenous injection of C. glabrata at varying doses (10
7 to 10
8 cells
per mouse) with different immune system status (immuno-
competent and immuno-suppressed) and in different mice back-
grounds [37,38]. Depending on the initial infection doses and the
mice genetic background, not only CFU counts in target organs
(kidneys, spleen and liver) differed by several logs (from 10
5 to
10
8 CFU per g infected tissue) over the duration of the experiments
but also mice survival was varying. As compared to C. albicans, C.
glabrata was consistently much less pathogenic. Inourstudy,we have
followed protocols established recently [17,21] and used different
immune status regimen to enable valid conclusions on the
relationship between azole resistance and virulence. Our findings
that C. glabrata resistant strains are both more virulent in mice and
less susceptible to azoles in vitro/in vivo as compared to wild type
isolates strongly suggest a gain in fitness for the resistant isolates. As
shown in this study (Figure 9B), the azole-resistant population did
effectively take over the azole-susceptible isolates in the absence of
drug selection. We showed that it is the presence of GOF mutations
rather than the presence of CgPDR1 that accounts for increased
virulence. On the opposite to known C. glabrata mutants (such as
ace2D) for which hypervirulence was associated with formation of
pseudo-hyphae [39], the morphology of azole-resistant isolates
tested here was not altered and therefore GOF mutations in
CgPDR1 are likely to account for the observed phenotype.
Hypervirulence has been also observed in other fungal species such
as Cryptococcus neoformans where perturbation in cAMP signalling by
inactivation of PKR1 (encoding the PKA regulatory subunit)
resulted in capsule overproduction [40]. Even though other C.
glabratainfectionmodelsremaintobetested,thisistoourknowledge
thefirstexample ofin vivo acquired mutationsina fungal gene witha
positive impact on in vivo fitness. This highlights a need of carefully
monitoring drug resistance of C. glabrata in infected patients, since
increased virulence observed here may also have a negative impact
on the outcome of the disease. In C. glabrata, the gain in fitness may
have favoured an important proportion of azole-resistant C. glabrata
isolates with ABC transporter upregulation [4,13]. This is in
contrast with studies on molecular epidemiology of drug resistance
performed with other fungal pathogens, where resistance develops
by more diverse resistance mechanisms, thus raising the question
whether the gain of fitness mediated by CgPDR1 is a feature unique
for C. glabrata. It will be therefore interesting to test whether
transcriptional activators of drug resistance genes have similar
effects on virulence and fitness in other important fungal pathogens.
How CgPDR1 GOF mutations may affect virulence is still
unknown. Nevertheless, published microarray experiments com-
paring a wild type C. glabrata isolates with a resistant strain
expressing a mutated form of CgPdr1p may help identifying genes
having a putative role in the virulence on the basis of differentially
expressed genes [14]. Even though the number of differentially
regulated genes is high in this study, several genes involved in stress
response, resistance to DNA damage and cell wall structure are
upregulated in the azole-resistant isolate, all of which may
contribute individually or in combination to modulate the
virulence of C. glabrata. Further studies are therefore necessary to
address the involvement of these genes in virulence.
Our results demonstrate that CgPDR1 GOF mutations alone are
responsible for fluconazole treatment failure in a murine model. In
most cases, animals infected with isolates containing GOF
mutations were not responding to fluconazole treatment on the
basis of CFU counts in specific organs (Figure 10 and Figure S5).
Fluconazole is not considered as a therapeutic option for C. glabrata
infections in human but served here as a compound to test the
effect of GOF mutations on treatment outcome. Our results
showed that a C. glabrata isolate with a low azole MIC can still
respond to fluconazole treatment. A reduction of C. glabrata CFU
counts in the range observed in the present study in azole-treated
animals (approximately 1.5 logs) is not consistently reported in
experimental C. glabrata candidiasis [41–44]. These variations
probably reflect the technical difficulties behind the establishment
of a disease by C. glabrata in different animal models but could also
be the result of inappropriate drug regimen. Having determined
conditions necessary to establish a C. glabrata infection and to
respond to drug treatment by a corresponding drug dosage, our
study could demonstrate that in vitro fluconazole resistance was well
correlated with in vivo resistance. Because GOF mutations in
CgPDR1 are also responsible for increased virulence, drug
treatment faces the challenges of both higher fungal loads and
acquired resistance. Under these conditions, the failure of drug
treatment is more likely. Besides the role of CgPDR1 GOF
mutations in azole treatment failure, CgPDR1 was shown to play a
critical role for the response of C. glabrata during fluconazole
treatment as observed by the sharp decrease in fungal tissue
burden after treatment in animals infected with mutants lacking
CgPDR1. Together with the recent discovery that CgPDR1
possesses functional domains used as drug ligands and therefore
potential sites for inhibitors [16,45], our data suggest that
inhibition of CgPDR1 could shortcut fitness and potentiate azole
therapy. Future studies are therefore necessary to explore this
possibility.
Materials and Methods
Strains and Growth Media
The C. glabrata strains used in this study are listed in Table S1.
One hundred twenty two clinical isolates of C. glabrata and were
recovered from different specimens (e.g. blood, urine, vagina,
sputum) of patients. Strains with the prefix ‘‘BPY’’ were collected
at the Universita ` Cattolica del Sacro Cuore, Rome, Italy. Strains
with the prefix ‘‘DSY’’ were collected at the University Hospital
Center, Lausanne (Switzerland) except strains DSY1166,
DSY1169, DSY1174, DSY1176, DSY1180, DSY1185 that were
provided by from Nippon Roche Research (Kanagawa, Japan).
Strains DSY2724, DSY2725, DSY2726, DSY2731, DSY2746
were obtained from J.-P. Bouchara at the Centre Hospitalier
d’Angers (France) and strains DSY2769, DSY2770 from M.-E.
Bougnoux at the Necker Hospital (Paris, France). Strains were
stored in 20% glycerol stocks at 280uC and cultured on either
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medium YNB (0.67% yeast nitrogen base plus 2% glucose) at
30uC when necessary. For solid media, 2% agar was added. YNB
with appropriate amino acids and bases was used as a selective
medium after transformation of yeast strains [10]. YEPG (1%
yeast extract, 2% peptone, 3% glycerol, 1% ethanol) agar plates
was used to test C. glabrata strains for petite growth phenotype.
YPD agar plates containing nourseothricin (clonNAT, Werner
BioAgents) at 200 mgm l
21 were used as a selective medium for
growth of yeast transformant strains. Drugs were obtained from
the following sources: fluconazole (Pfizer), itraconazole and
ketoconazole (Janssen). Escherichia coli DH5a was used as a host
for plasmid construction and propagation. DH5a was grown in
Luria-Bertani broth or on Luria-Bertani agar plates supplemented
with ampicillin (0.1 mg ml
21) when required.
Drug Susceptibility Assays
The C. glabrata strains were tested for azole susceptibility with the
broth microdilution method described in the CLSI (formerly
NCCLS) document M27-A2 (National Committee for Clinical
Laboratory Standards, 2002). Briefly, aliquots of 1.5
(61.0)610
3 cells ml
21 were distributed to wells of a microtitre plate
in RPMI 1640 containing 2% glucose and incubated at 35uCf o r
48 h. Endpoint readings were recorded with an automatic plate
reader (Multiskan Ascent, Thermo) and the lowest azole concentra-
tion that reduced growth to 50% of that of the drug-free control was
defined as the MIC. Susceptibility to fluconazole of C. glabrata strains
was tested qualitatively by spotting serial dilutions of overnight-grown
yeast broth cultures onto YPD agar plates with different drug
concentrations,asdescribedpreviously [10]. After incubation at30uC
for 48 h, yeast spots were visualized onto plate surfaces.
Sequencing of CgPDR1
C. glabrata genomic DNA was used as a template to amplify by
PCR CgPDR1 using the primers CgPDR1-EcoRI (59-ATACCA-
GAATTCGGTCTCCGCTACAGGTTATA-39) and CgPDR1-
BamHI (59-AAGTTTGGATCCAACGTTGTTGAGAAGG-
TATT-39). The resulting PCR product was sequenced with the
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosys-
tems) according to the manufacturer protocol.
Immunoblotting
C. glabrata cell extracts for immunoblotting were prepared by an
alkaline extraction procedure as described previously [46].
Detection of CgCdr1p and CgCdr2p was performed as described
previously [9]. Signals were revealed by exposure to Amersham
Hyperfilm MP films (GE Healthcare).
Quantitative Real-Time RT-PCR
Total RNA was extracted from log phase cultures with an
RNeasy Protect Mini kit (Qiagen) by a process involving
mechanical disruption of the cells with glass beads and an
RNase-free DNase treatment step as previously described [13].
Expression of the CgCDR1, CgCDR2 and CgSNQ2 genes was
quantitatively assessed with real-time RT-PCR in an i-Cycler iQ
system (Bio-Rad). All primers and probes [13] were designed with
Beacon Designer 2 (version 2.06) software (Premier Biosoft
International) and synthesized by MWG Biotech (Ebersberg,
Germany). RT-PCRs were carried out as previously described
[13]. Each reaction was run in triplicate on three separate
occasions. For relative quantification of the target genes, each set
of primer pairs and the Taqman probes were used in combination
with the primers and probe specific for the CgACT1 reference gene
in separate reactions [17]. Changes (n-fold) in gene expression
relative to that of DSY562 (azole-susceptible control isolate) were
determined from CgACT1-normalized expression levels. A two-fold
increase in the expression level of each gene was arbitrarily
considered as significant [17]. Expression of CgPDR1 in related
azole-susceptible and azole-resistant clinical isolates was deter-
mined by real-time RT-PCR in an ABI Prism 7000 (Applied
Biosystems). Each reaction was run in triplicate on three separate
occasions. CgPDR1 quantification was performed using the primers
CgPDR1-for (59-AGCCTTGCCGATAGTCATAC-39) and
CgPDR1-rev (59-AAGGTCAGGGCATACTTCAG-39) using
the QuantiTect SYBR Green PCR Kit (Qiagen). CgPDR1 alleles
sequenced in this work can be found under GenBank accession
numbers FJ550215 to FJ550284. CgPDR1 expression was normal-
ized by CgACT1 expression levels using the specific primers
CgACT1-for (59-TTCCAGCCTTCTACGTTTCC-39) and
CgACT1-rev (59-TCTACCAGCAAGGTCGATTC-39).
RNA Hybridization
Small-scale isolation of RNA from C. glabrata was performed as
previously described [10]. Five mg of denaturated RNA was
transferred under vacuum onto GeneScreen Plus membranes
(Perkin Elmer) using the slot-blotter MINIFOLD II (Schleicher &
Schuell). Membranes were washed in 26 SSC and dried during
2 h at 80uC under vacuum. Probes were labelled by random
priming with [a-
32P]dATP using the Mega Labeling kit (GE
Healthcare) according to the instructions of the manufacturer.
Radioactive signals were revealed by exposure to Amersham
Hyperfilm MP films (GE Healthcare). Signals obtained in blotted
membranes were quantified by counting of radioactivity with the
help of a Typhoon Trio (GE Healthcare). The CgPDR1 probe
corresponds to the entire open reading frame and was generated
by PCR using primers CgPDR1-SphI (59-GCGCAAAGCATG-
CATG CAAACATTAGAAACTACA-39) and CgPDR1-10 (59-
TCCTTAAGCCCGATAAGG-39). The CgACT1 probe was used
as an internal standard and was generated by PCR using primers
CgACT1F (59-TTGACAACGGTTCCGGTATG-39) and
CgACT1R (59- CCGCATTCCG TAGTTCTAAG-39).
Expression of CgPDR1 Alleles in SFY53
To express CgPDR1 alleles in an azole-susceptible strain, the
CgPDR1 ORF flanked by 1.2 kb-upstream and 0.5 kb-downstream
regions was amplified by PCR from DSY2235 and DSY2234
genomic DNA using the primers CgPDR1-EcoRI and CgPDR1-
BamHI (see above) and inserted into pCgACU-5 to yield pSF18
and pSF19, respectively. These plasmids were used to transform
SFY53 (DSY562 pdr1D) to obtain SFY72 and SFY73, respective-
ly.
Disruption of CgPDR1
pSF2, in which the SAT1 flipper is flanked by CgPDR1 upstream
and downstream sequences, was used for the disruption of CgPDR1
in DSY562 and DSY565 [17]. This plasmid was linearized by
digestion with KpnI and SacI and transformed into DSY562 and
DSY565 to obtain after selection of transformants on nourseo-
thricin-containing YPD plates the CgPDR1 deletion strains SFY92
and SFY93, respectively.
Replacement of CgPDR1 Alleles
For CgPDR1 replacement in SFY92 and SFY94, FLP-mediated
excision of the SAT1 cassette was first induced by growing the cells
for 4 h at 30uC in YCB-BSA medium (23.4 g l
21 yeast carbon
base and 4 g l
21 bovine serum albumin; pH 4.0). One hundred to
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thricin (15 mgm l
21) and grown for 48 h at 30uC to obtain
nourseothricin-sensitive strains SFY93 and SFY95, respectively.
The revertant strains generated in this study were obtained by
transformation of the pdr1D mutants SFY93 and SFY95 with
linearized plasmids containing the SAT1 marker and the PCR-
amplified CgPDR1 open reading frames of the strains listed in
Table 1 as described previously [17]. Briefly, the complete CgPDR1
ORF flanked by 500 bp was amplified by PCR from genomic DNA
ofthefirsteightstrainpairsofTable1usingprimersCgPDR1-KpnI
(59-GCAAAGGTACCCGTTGATCATTATAATTGTGGGTA-
AA-39)a n d3 9UTR-PDR1-SacI(59-GCGCAAAGAGCTCGAGT-
TACAGACGACCAACGTGTCG-39) and inserted into pBlue-
script II SK(+). These plasmids were amplified by PCR using the
primers CgPDR1-EcoRI inv (59-GCGCAAAGAATTCGTTGA-
GAAGGTATTAAGAACTTC-39)a n d3 9UTR-PDR1-NotI (59-
GCGCAAAGCGGCCGCTACCGAAAGTTCGGTAAATCTA-
GG-39). The resulting PCR products were digested by EcoRI and
NotI and ligated to a 1.8 kb EcoRI/NotI fragment containing SAT1
from pSFS1. The resulting plasmids were linearized by KpnIa n d
SacI and transformed into SFY93 and SFY95 to obtain, after
selectionoftransformants onnourseothricin-containingYPDplates,
the CgPDR1 revertant strains listed in Table S1.
Animal Studies
Female BALB/c mice (20 to 25 g; Harlan Italy S.r.l) were
housed in filter-top cages with free access to food and water, and
were used for all in vivo experiments with the approval by the
institutional Animal Use Committee (Universita ` Cattolica del
Sacro Cuore, Rome Roma, Italy). To establish C. glabrata
infection, mice were injected into their lateral vein with saline
suspensions of the C. glabrata strains (each in a volume of 200 ml).
In virulence studies, a group of ten mice was established for
each yeast strain. In a first experiment series, immuno-competent
or immuno-suppressed mice were inoculated with 4610
7 colony-
forming units (CFU) of the yeasts [21]. Mice were rendered
neutropenic by intraperitoneal administration of cyclophospha-
mide (200 mg kg
21 of body weight per day) three days before
challenge and on the day of infection. After seven days, mice were
sacrificed by use of CO2 inhalation, and target organs (liver, spleen
and kidney) were excised aseptically, weighted individually and
homogenized in sterile saline by using a Stomacher 80 device (Pbi
International) for 120 s at high speed. Organ homogenates were
diluted and plated onto YPD. Colonies were counted after two
days of incubation at 30uC, and the numbers of CFU g
21 of organ
were calculated. In a second experiment, mice were rendered
neutropenic as above described and were injected with
7610
7 CFUs of the strains [22]. Mice were monitored with
twice-daily inspections and those that appeared moribund or in
pain were sacrificed by use of CO2 inhalation.
In fluconazole treatment studies, two groups of tenmice, one for
drug treatment and one for control, were established with each
strain. Neutropenia was induced as above described on days 24,
+1 and +4 post-infection [20]. Mice were injected with
4610
7 CFUs [20] of the strains and were sacrificed one day after
the end of therapy to assess organ fungal burden (see above). Mice
received daily intraperitoneal injections of 100 mg kg
21 flucona-
zole diluted in saline [41] and the treatment was initiated 24 h
after challenge and continued through post-infection day 7.
CFU counts were analysed with non-parametric Wilocoxon
Rank sum tests, while mean survival times were compared among
groups by using the long-rank test. A P-value of less than 0.05 was
considered to be significant. All relevant P- values calculated in this
study are listed in Table S3.
Measurement of SFY114 and SFY115 Fitness In Vitro And
In Vivo
Strains SFY114 and SFY115 were grown overnight in YEPD
and diluted to a density of 5610
6 cells ml
21. Equal volumes of
each culture were mixed together and cultures were grown under
constant agitation at 30uC for 24 h. Growth of SFY114, SFY115
and the co-culture was determined at 2 h, 4 h, 8 h and 24 h by
measuring the absorbance at 540 nm and by plating diluted
samples of the cultures onto YEPD agar plates. Since SFY115 is
able to grow on high concentrations of fluconazole in contrast to
SFY114, the relative proportion of both strains in the co-culture
was determined by replicating colonies onto YEPD agar
containing 30 mg
21 ml of fluconazole. After incubation at 30uC
for 48 h, colonies on YEPD plates and on plates containing
fluconazole were counted.
For in vivo fitness assays, cultures of strains SFY114 and SFY115
were diluted to a density of 4610
7 CFUs and these suspensions
were used to infect three groups of mice (four per group). Two
groups of mice were infected with SFY114 and SFY115,
respectively, and the third group with both strains mixed at a
ration of 1:1. At two, four and seven days post-infection, mice were
sacrificed and kidneys homogenates were obtained (see above).
Diluted samples from these homogenates were plated onto YEPD.
Colonies grown after two days of incubation at 30uC were
replicated onto YEPD plates containing fluconazole (30 mg
21 ml)
to determine the relative proportion of both strains as above-
described.
Supporting Information
Figure S1 Immunodetection of CgCdr1p and CgCdr2p in C.
glabrata. Panel A: Sequential and related isolates. Panel B:
Unrelated clinical isolates. Proteins extract were separated by
SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-
CgCdr1p and anti-CgCdr2p antibodies as described previously
[10]. MICs to fluconazole were determined by broth microdilution
method in accordance with the CLSI M27-A2 document
(National Committee for Clinical Laboratory Standards, 2002).
Found at: doi:10.1371/journal.ppat.1000268.s001 (3.03 MB TIF)
Figure S2 Mitochondrial dysfunction in clinical isolates. Panel
A: Ability of C. glabrata clinical isolates to grow on medium
containing glucose (YEPD) or glycerol (YEPG) as carbon source.
Azole-susceptible strains DSY2281, DSY2324 and BPY41 are
respiratory competent while their matched azole-resistant isolates,
DSY2282, DSY2325 and BPY41, respectively, show mitochon-
drial dysfunction. Panel B: Staining of C. glabrata mitochondrial
DNA with the fluorescent dye SYTO18 and examined by either
phase-contrast (Nomarsky) or fluorescence microscopy. Mitochon-
drial DNA was stained using SYTO18 (Molecular Probes). C.
glabrata cells growing exponentially in YEPD at 30uC were
harvested, suspended in 10 mM HEPES buffer pH 7.4 with 5%
glucose, at 10
6 cells ml
21 and mixed with SYTO18 to a final
concentration of 10 mM to stain at 25uC for 5 min. The stained
cells were washed and suspended with 10 mM HEPES and
observed under a fluorescence microscope.
Found at: doi:10.1371/journal.ppat.1000268.s002 (1.47 MB TIF)
Figure S3 Expression of CgPDR1 in matched pairs of clinical
isolates (DSY), in revertant strains (rev) and in a pdr1D mutant
(SFY92). RNA was isolated from log phase cultures, slot-blotted to
membranes and hybridized with the indicated gene probes.
CgACT1 served as internal control. Signals obtained in blotted
membranes were quantified by counting radioactivity with
phosphor imaging. Signals obtained for CgPDR1 were normalized
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expression in revertant strains relative to the clinical isolates
expressing the same CgPDR1 allele. Since slot-blot quantification
of CgPDR1 expression was comparable to real time RT-PCR (see
Fig. 3), only slot-blot data are shown. CgPDR1 alleles present in
each strain (‘‘DSY’’ for clinical strains and ‘‘rev’’ for revertant
strains) are named according to their strain numbers and to their
associated CgPDR1 amino acid substitution (in superscript).
Found at: doi:10.1371/journal.ppat.1000268.s003 (1.94 MB TIF)
Figure S4 Virulence assays in murine infection models. Panel A:
Fungal tissue burdens in spleen from immuno-competent BALB/c
mice infected intravenously with 4610
7 viable cells of C. glabrata
strains. Mice were sacrificed at day 7 post-infection and results,
which are expressed as CFUs per gram of tissue, represent means
of values recorded separately for each of the ten mice. Geometric
means are indicated by horizontal bars and asterisks indicate
statistically significant differences (*: P,0.05; **: P,0.01; ***:
P,0.001). NS indicates no significance (P.0.05). Prism 5.0 was
used for statistical analysis and data were processed with non-
parametric Wilocoxon Rank sum tests. Comparisons are indicated
in the Figure (see Table S3 for details) and associate selected data
points. The origin of each strain is indicated. Strain background
(DSY562 or DSY565) is indicated by filled or empty symbols,
respectively. The pdr1D mutants from strains DSY562 and
DSY565 correspond to SFY92 and SFY94, respectively. Rever-
tants constructed from pdr1D mutants are indicated by the re-
introduced gain of function mutation or by the re-introduced wild
type CgPDR1 allele from DSY562. Panel B: Fungal tissue burdens
in spleen from immuno-suppressed mice infected intravenously
with 4610
7 viable cells of C. glabrata strains. BALB/c mice were
rendered neutropenic by intraperitoneal administration of cyclo-
phosphamide (200 mg kg
21 of body weight per day) three days
before challenge and on the day of infection. Mice were sacrificed
at day 7 post-infection. Panel C: Fungal tissue burdens in liver
from immuno-competent mice. Panel D: Fungal tissue burdens in
liver from immuno-suppressed mice.
Found at: doi:10.1371/journal.ppat.1000268.s004 (0.71 MB TIF)
Figure S5 Efficacy of azole treatment in C. glabrata. Panel A:
Fungal tissue burdens in spleen from untreated (filled symbols) and
fluconazole-treated (open symbols) animals. Panel B: Fungal tissue
burdens in liver from untreated (filled symbols) and fluconazole-
treated (open symbols) animals. Fluconazole (100 mg/Kg/day)
was administered by intra-peritoneal injection in immuno-
suppressed mice as described in Material and Methods. Treatment
was initiated 24 h after inoculation (day 1 post-infection) and
continued through day 7 post-infection. Mice were injected with
4610
7 CFU of each investigated strain and organ homogenates
were obtained from ten mice per group that were sacrificed and
necropsied on day 8 post-infection. Results, which are expressed as
CFUs per gram of tissue, represent means of values recorded
separately for each of the ten mice. Geometric means are indicated
by horizontal bars and asterisks indicate statistically significant
differences between two conditions (*: P,0.05; **: P,0.01; ***:
P,0.001). NS indicates no significance (P.0.05). Prism 5.0 was
used for statistical analysis and data were processed with non-
parametric Wilocoxon Rank sum tests (see Table S3 for details).
Found at: doi:10.1371/journal.ppat.1000268.s005 (0.63 MB TIF)
Table S1 Strains used in this study.
Found at: doi:10.1371/journal.ppat.1000268.s006 (0.34 MB
DOC)
Table S2 Position of mutations of all CgPDR1 alleles.
Found at: doi:10.1371/journal.ppat.1000268.s007 (0.15 MB XLS)
Table S3 Details of statistical analysis.
Found at: doi:10.1371/journal.ppat.1000268.s008 (0.27 MB
DOC)
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